24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case for each in 2016.
ThinkstockIn the second quarter of this year, U.S. corporate profits totalled $1.8 trillion after taxes. Massive corporate profit is not limited to the United States, although many of the world’s most profitable…
ThinkstockJanssen Biotech announced that the U.S. Food and Drug Administration (FDA) approved Yondelis (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior…
Chris Lange ThinkstockOctober 15, 2015: Markets opened higher on Thursday following a strong showing for stocks in both Asia and Europe. Biotech stocks continue to get new life, helping overcome some softness in tech…
Johnson & Johnson reported mixed third-quarter 2015 results before markets opened Tuesday morning.
Paul Ausick Johnson & Johnson is scheduled to report its third-quarter financial results before the markets open on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of some of the Dow Jones Industrial Average companies that are reporting their quarterly results this week.
Monday's top analyst upgrades, downgrades and initiations include AutoZone, Discover Financial Services, IBM, Microsoft, Twitter, Viacom and Wynn Resorts.
Its stock has suffered, but it is possible that Achillion’s interim trial results may have put the company back on the right track.
Chris Lange thinkstockSeptember 3, 2015: Markets opened higher on Thursday after the European Central Bank president indicated that the ECB would continue quantitative easing program. Markets in China and Hong Kong were closed for a…
thinkstockAugust 28, 2015: Markets opened lower on Friday, and except for a brief visit above the break-even line, the blue chips traded lower all day. Crude oil settled at $45.22, up more…
Led by Apple and Intel, the Dow 30 stocks have engineered a significant recovery since the opening bell rang Monday morning.
In a new research report, the technical team at RBC highlight stocks and sectors that are working and are clearly safer than crowded momentum stocks.
Where will the most brilliant investor in the world put his money if the markets collapse? Perhaps into some of the safe harbor stocks he already holds.
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
